



iFabric #
CORPORATION

INVESTOR PRESENTATION FEBRUARY 2022

TSX: IFA; OTC: IFABF



A preliminary prospectus (the "Preliminary Prospectus") containing important information relating to the securities described in this presentation (the "Investor Presentation") has been filed with the securities regulatory authorities in each province and territory of Canada (other than Quebec). A copy of the Preliminary Prospectus, and any amendment, is required to be delivered with this document. The Preliminary Prospectus is still subject to completion. There will not be any sale or any acceptance of an offer to buy the securities until a receipt for the final prospectus has been issued. This Investor Presentation does not provide full disclosure of all material facts relating to the securities offered. Investors should read the Preliminary Prospectus, the final prospectus and any amendment for disclosure of those facts, especially risk factors relating to the securities offered, before making an investment decision.

DISCLAIMER

Included in this Investor Presentation is certain forward-looking information related to iFabric Corp. (the "Company"), as such term is defined under applicable Canadian securities laws. This information relates to future events or future performance and reflects management's expectations and assumptions regarding the growth, results of operations, performance and business prospects and opportunities of the Company. Such forward-looking information reflects management's current beliefs and is based on information currently available to management of the Company and a number of assumptions that management believed were reasonable on the day such forward-looking information was presented. Refer, in particular, to the relevant sections of the Investor Presentation, the Prospectus and the documents incorporated by reference therein, for a discussion of certain assumptions management has made in presenting forward-looking information, which sections are incorporated by reference therein. In some cases, forward-looking information can be identified by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "intend", "believe", "estimate", "predict", "potential", "continue" or the negative or grammatical variations of these terms or other similar expressions concerning matters that are not historical facts. In particular, information regarding the Company's future operating results and economic performance is forward-looking information. A number of factors could cause actual events or results to differ materially from the events and results discussed in the forward-looking information. See "Risk Factors" in the Preliminary Prospectus.

Forward-looking information relates to analyses and other information that are based on forecasts of future results, estimates of amounts not yet determinable and other uncertain events. Forward-looking information, by its nature, is based on assumptions, including those described below, and involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements to differ materially from those expressed in the forward-looking information. Any forecasts or forward-looking predictions or statements cannot be relied upon due to, among other things, changing external events and general uncertainties of the business. Results indicated in forward-looking information may differ materially from actual results for a number of reasons, including without limitation: completion of the Offering; the intended use of proceeds from the Offering; expectations regarding future revenues, earnings, capital expenditures and operating and other costs; business strategy and objectives; market trends; the sufficiency of cash and working capital for future operating activities; expectations for other economic, business, regulatory and/or competitive factors related to the Company or the industries it competes in generally; anticipated production capacity; and other events or conditions that may occur in the future.

Investors are cautioned that forward-looking information is not based on historical facts but instead is based on reasonable assumptions and estimates of management of the Company at the time they were made and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information. Such factors include, among others, risks relating to competition; general economic conditions and consumer spending; reliance on key licensing and distribution agreements; economic dependence on key customers; dependence on key personnel; rapid technological advancements in the industry; the Company's ability to maintain proprietary protection of its intellectual property; future changes in government regulation, dependence on customer adoption; and the expected or potential impact of the novel coronavirus ("COVID-19") pandemic, as well as the risk factors described under the heading "Risk Factors" in the Preliminary Prospectus. Prospective purchasers are cautioned that the foregoing list is not exhaustive of all factors and assumptions which may have been used. Although the Company has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such forward-looking information and statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such information and statements. Accordingly, prospective purchasers should not place undue reliance on forward-looking information and statements, including the documents incorporated herein by reference, as statements containing forward-looking information involve significant risks and uncertainties and should not be read as guarantees of future results, performance, achievements, prospects and opportunities. The forward-looking information and statements contained herein are presented for the purposes of assisting prospective purchasers in understanding the Company's expected financial and operating performance and the Company's plans and objectives and may not be appropriate for other purposes.

All forward-looking information in this Investor Presentation, the Preliminary Prospectus and the documents incorporated by reference into the Preliminary Prospectus, is qualified by these cautionary statements. The forward-looking information is made only as of the date that such information is made, and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required under applicable securities regulations.

An investment in the Units (as defined in the Preliminary Prospectus) is highly speculative and involves a high degree of risk, and should only be made by persons who can afford the total loss of their investment. Investors should carefully consider the risk factors described in the Preliminary Prospectus before purchasing the Units. Prospective investors are advised to consult their legal counsel and other professional advisors in order to assess income tax, legal and other aspects of the investment. See "Forward-Looking Information" and "Risk Factors" in the Preliminary Prospectus.

Prospective purchasers should rely only on the information contained or incorporated by reference in the Preliminary Prospectus. The Company and the Underwriters (as defined in the Prospectus) have not authorized anyone to provide prospective purchasers with information different from that contained or incorporated by reference in the Preliminary Prospectus. The Underwriters are offering to sell and seeking offers to buy the Units only in jurisdictions where, and to persons to whom, offers and sales are lawfully permitted. Prospective purchasers should not assume that the information contained in the Preliminary Prospectus is accurate as of any date other than the date on the cover page of the Preliminary Prospectus.

Prospective purchasers are advised to consult their own tax advisors regarding the application of Canadian and U.S. federal income tax laws to their particular circumstances, as well as any other provincial, state, foreign and other tax consequences of acquiring, holding or disposing of the Units, including the Canadian federal income tax consequences applicable to a foreign controlled Canadian corporation that acquires the Units.

This Investor Presentation is qualified in its entirety by reference to, and must be read in conjunction with, the information contained in the Preliminary Prospectus. A prospective investor is not entitled to rely on parts of the information contained in this presentation to the exclusion of others.

TWO DIVISIONS

Socially responsible fabric technologies as well as intimates and wardrobe solutions



INTELLIGENT FABRIC TECHNOLOGIES NORTH AMERICA INC. | IFTNA

IFTNA is developing a suite of performance additives for textiles, including antimicrobial and antiviral textiles as well as solutions for medical, athletic, military, consumer & corporate apparel, bedding, linens and other categories. It sells chemical solutions to third parties and manufactures its own private label performance apparel. It is launching its own brand of performance and travel apparel as well as personal protective equipment.



[Source: Tumi Canada](#)



[Source: Lolelif.com](#)



COCONUT GROVE INTIMATES

Coconut Grove Intimates has been supplying the fashion industry with unique and superior intimate apparel collections. It is focused on private label, Maidenform and in-house brands and distributes products for some of the most well known intimates brands globally.



COMPANY HIGHLIGHTS



INTELLIGENT FABRICS THAT ADDRESS UNMET CONSUMER AND MEDICAL NEEDS

Suite of proprietary chemical formulations that render fabrics, foams, plastics, and numerous other surfaces intelligent. Portfolio includes antimicrobials, sustainable water repellents, moisture wicking and UV protection technologies.



GROWING ANTIMICROBIAL MARKET

The Global **Antimicrobial Textiles Market** was estimated at **US\$8.5 Billion¹ in 2020** and is projected to reach **US\$11.5 Billion by 2027**. Our flagship PROTX2[®]AV chemistry has been 3rd party certified tested against Influenza A&B, H1N1, MRSA, E. Coli, COVID-19, VRE, and Norovirus.



SIGNIFICANT UPSIDE POTENTIAL WITH ADVANCED US EPA CLAIM

In the final stages of potentially becoming the first Company globally with an advanced anti-bacterial and anti-viral claim.



MAJOR BRAND NAME CUSTOMERS

Under Armour, Lululemon, Walmart, Target, TUMI, The North Face, Hanes, Kohl's and Amazon are among top customers.



MANAGEMENT ALIGNED

Management ownership is 64%.

¹https://www.researchandmarkets.com/reports/5029859/antimicrobial-textiles-global-market-trajectory?utm_source=MC&utm_medium=Email&utm_code=mzr38yrl8&utm_ss=17&utm_campaign=1404873+-+Antimicrobial+Textiles+-+Global+Market+Trajectory+%26+Analytics&utm_exec=adke277mtd

IFTNA TECHNOLOGY PORTFOLIO

IFTNA has developed a number of products that are partnered with household brands



PROTX2[®] AV
Antiviral, antibacterial & anti-odour



PROTX2[®]
Antibacterial, antimicrobial & anti-odour



REPELTX ECO PLUS
Fluorine free water repellent



OMEGA⁺
Accelerated joint & muscle recovery



TEMP^{+X}
Thermo and cooling regulator



BIOTX
Metal-free antimicrobial agent



DREAMSKIN[®]
Encourages healthy & hydrated skin



APOLLO
Body odour neutralizer



DRIFORCE
Evaporation enhancement



ENGUARD
Insect repellent



DRYTX[®]
Moisture wicking technology



UVTX
Superior UV protection



imPRINT
Wicks away moisture using fabric gateways exposing logos and patterns


PROTX² AV

METAL-FREE

ANTIVIRAL, ANTIBACTERIAL & ANTI-ODOUR AGENT

PROTX²AV a patent pending anti-viral, antibacterial, and anti-odour textile technology. It **is the world's first antiviral textile technology proven to kill greater than 99.9% of SARS-COV-2 (COVID-19) in 10 minutes.** PROTX²AV broad spectrum antiviral properties may also reduce the risk and speed of contamination and transmission.

- To the knowledge of the Company, it is the world's first antiviral, antibacterial and anti-odour technology seeking kill claim registration with the US EPA.
- An effective chemical solution for reducing the spread of nosocomial infections on soft and hard surfaces.
- 3rd party certified by independent laboratories against COVID-19, MRSA, C-Diff, VRE, E. Coli, Norovirus, and H1N1.
- Currently selling a suite of products to Under Armour (sports masks, gaiters), Tumi, Springs Window Fashions (blinds, curtains, etc.) and a Canadian Big Box Retailer.
- Applications span beyond healthcare to hospitality, military, and sportswear industries.



PRIVATE BRAND LAUNCHES



VERZUS ALL Apparel® is IFTNA's privately owned brand, that specializes in developing forward thinking technology infused performance and travel apparel, showcasing our entire suite of technologies. We have designed, developed and patented an extensive range of Men's and Women's products including:

Sweatshirts and Sweatpants | Underwear | Loungewear | Tights/Leggings | Shirts & Tops | Hats

For launch year we have an expected revenue of \$5M with a 20-25% margin. Year 2 is an expected \$10M in revenues with 40-55% margin.

MENS



WOMENS




PRIVATE BRAND LAUNCHES



FRONTLINE® is IFTNA's healthcare driven privately owned brand launched Spring 2021 specializes in **PROTX2®AV** treated personal protective equipment including:

Reusable and Disposable Masks | Gloves | Gowns | Other Necessary PPE

LIVE NOW AT
www.IFTNA.com/shopfrontline



Debuting Summer 2021, IFTNA is offering two new private label brands exclusively sold through Amazon PRIME's Program. **Underit®** will offer a base layer program catered to today's active Men, Women and Kids. **A Weeks Worth** will be offering 7 packs of our exclusive line of underwear ranging from Men's and Boy's boxers to Women's and Girl's seamless underwear. All programs will be utilizing our **PROTX2®** technology as well as **DRYTX®**.



COCONUT GROVE INTIMATES

Over the last 30 years, we have continued to stay on top of market trends to design, develop and supply the fashion industry with unique solution bras and bra accessories for every possible occasion. CGI is part of a niche market with aging competition and room for exponential growth.



25+ YEARS OF PROFITABILITY

Over 25 years of profitable operations with gross margins over 50%



PRIVATE LABEL

Distribution across Canada & USA



PATENTS

Innovative registered patents as well as new patent pending products.



BRANDS



FLAGSHIP RETAILERS



FINANCIAL RESULTS


FQ4 2021 Highlights (\$CAD)

- Revenues of \$5.2M compared to \$4.2M in FQ4 2020 (+44%)
- Gross profit as a percentage of revenue decreased to 32%, compared to 48% FQ4 2020, as a result of sales mix
- Net earnings after tax of \$203,165 versus \$357,092 in FQ4 2020 for the reasons mentioned above.
- Strong working Capital position of \$19.6M

2021 Fiscal Year End Highlights (\$CAD)

- Total revenue increased by 72% to \$19.8M compared to \$8.2M for F2021
- Revenue in the Intelligent Fabrics segment increased from \$8.1M in FY2020 to \$15.7M (+94%)
- Net earnings after tax of \$2.37M compared to a net loss \$617k

IFABRIC GROUP




CAPITAL STRUCTURE

TSX LISTED, SYMBOL: IFA OTC: IFABF

Share Price (01/18/22)	\$3.00
Shares Outstanding (Basic)	29.5M
Options	1.9M
Warrants	2.9M
Shares Outstanding (Fully Diluted)	34.4M
Market Capitalization	\$88.8M
52 Week Range	\$5.80/\$2.30
Working Capital	\$19.6M*
Long Term Debt	\$0.3M
Management Ownership	64%

Share Ownership



*As of June 30, 2021.

MANAGEMENT



HYLTON KARON

Group President & CEO

Graduated from Philadelphia University with a BSC degree in textile marketing and management, and now has over 35 years of experience in product development and marketing. Hylton's creative ability has resulted in the development of many successful and patented products which are sold both in North America and internationally.



GIANCARLO BEEVIS

President & CEO | IFTNA

A graduate with an Honours B.A. from York University, Giancarlo has been involved with the company for 15 years, contributing expert knowledge and is instrumental in the brand development of Intelligent Fabric Technologies North America. Giancarlo oversees the strategic direction of IFTNA and the development of products, brands and technologies.



HILTON PRICE

Group Chief Financial Officer

A Chartered Professional Accountant with over 40 years of experience covering a variety of industries and business. Hilton has been involved in most elements of the group's strategic planning and is responsible for financial oversight since the groups inception.



JASON GARAY

Chief Science Officer | IFTNA

Mr. Garay is the VP of Analytics and Informatics at Cancer Care Ontario (CCO). Jason was previously the Director, Communicable Disease Prevention and Control at Public Health Ontario. He is an Adjunct Professor at the University of Toronto and holds an MHS in Community Health and Epidemiology, a BSc in Occupational and Public Health, and a BSc (Honours) in Statistics and Psychology.

BOARD OF DIRECTORS

Dr. Mark Cochran

PhD | Chairman

Dr. Cochran is Executive Director of Johns Hopkins Medicine. His experience spans all levels of the drug discovery and development value chain, including operational and executive roles in the healthcare, venture capital, pharmaceutical, and biotech industries.

Hylton Karon

Director

Mr. Karon is the Group President and CEO of iFabric Corp.

Mark Greenspan

CA, CBV | Director

Mr. Greenspan was CFO of The Medipattern Corporation from September 2002 until February 2010. Prior to that, he spent 18 years at Scotiabank in various executive capacities. Prior to joining Scotiabank, he spent 8 years at KPMG where he specialized in mergers and acquisitions.

Hilton Price

Director

Mr. Price is the CFO of iFabric Corp.

Cameron Groome

Director

Cameron has served on the Microbix Board of Directors and Advisory Committee since 2012, and was appointed CEO in 2017. He has more than 25 years of experience in senior life sciences and finance roles and has been an executive, director, and advisor for public and private companies.

Giancarlo Beevis

Director

Mr. Beevis is the President and CEO of IFTNA, a division of iFabric Corp.

UPCOMING MILESTONES

**BRAND
LAUNCHES:
VERZUS ALL[®],
A WEEKS
WORTH[®], &
UNDERIT[®]**

**NEW
LICENSING
AGREEMENTS
AND
CONTRACTS**

**US EPA
ADVANCED
CLAIM
REGISTRATION**

**PROTX2[®] &
REPELTX[®]
CLINICAL
TRIALS**

**HARD SURFACE
RESEARCH AND
DEVELOPMENT**

APPENDIX



WORLDWIDE CHALLENGES

A GLOBAL PANDEMIC

- Amid the COVID-19 crisis, the global market for **Antimicrobial Textiles estimated at US\$8.5 Billion in the year 2020, is projected to reach a revised size of US\$11.5 Billion by 2027**
- The U. S. Accounts for Over **29.4% of Global Market Size in 2020, While China is Forecast to Grow at a 4.2% CAGR for the Period of 2020-2027**

HEALTHCARE ASSOCIATED INFECTIONS (HAI'S)

- Now one of the top 10 leading causes of deaths in the developed world (CDC, NIH)
- Textiles are a major source of HAI-causing pathogens and yet there is no effective way to keep them free of these pathogens during use
- **Healthcare providers' uniforms can be vectors that spread infections**
- **92% of hospital privacy curtains are contaminated with multiple infectious bacteria**
- **100,000 deaths** from hospital HAI's last year in the United States

CONSUMER DESIRE

- The consumer desire for eco-friendly sustainable controlled odour solutions that allow for more wear and less washing

PROTX2®

IFTNA'S FLAGSHIP TECHNOLOGY



THE BREAKTHROUGH

PROTX2® is a breakthrough in antibacterial, antimicrobial and anti-odour protection. When treated, each fiber is fundamentally transformed through PROTX2®'s technology providing proprietary protection.

PROTX2® in different dosages can be used in two distinct ways

1 HEALTHCARE, HOSPITALITY & FOOD SERVICE
as an **antimicrobial, antibacterial, and anti-odour agent**

2 ATHLEISURE & SPORTSWEAR
as an **anti-odour agent**

PATENT PORTFOLIO

Our portfolio of innovative patents answer today's market trends

TECHNOLOGIES

PROTX2® AVGuard
DUO POWER

PATENT PENDING
PROTX2® AVGuard


Our proprietary laundry additive with antiviral, antibacterial and anti-odour properties.

PROTX2®
AV

PATENT PENDING
PROTX2® AV


Our antiviral, antibacterial and anti-odour agent.

UNDERWEAR



PATENT PENDING
MESH SLING


Using the most advanced construction techniques and materials, we've created a mesh sling that provides optimum support and comfort.





PATENT PENDING
2-SIDED FLY

Our 2-sided patented fly design caters to the wearer's needs, whether they are left or right-handed, while providing all day comfort and support.

MASKS



PATENT PENDING
SLOTTED MASK
Triple layer constructed protective mask.



PATENT PENDING
HAT MASK


A protective mask designed with a clip feature to attach to hats.

BRA SOLUTIONS



PATENTED
BREAST LIFT

The perfect braless solution with a unique tab design providing customizable lift and a contoured natural shape.



PATENT PENDING
REVERSIBLE BRA

1 bra with 2 colour choices (nude and black) designed with double-sided silicone wings and dyed to match wing covers.

IN THE MEDIA


In light of the current worldwide pandemic, consumers and industry leaders have shown explosive interest for iFabric's innovative SARs CoV2 destroying technology PROTX2®AV sparking worldwide media coverage shown on the largest media outlets since our launch just this year.



MEN'S HEALTH
OCT. 16, 2020
Dwayne 'The Rock' Johnson Just Launched a Face Mask Created Specifically for Athletes



VOGUE NETHERLANDS
OCT. 14, 2020
Here's what you want to know about anti-microbial fashion



FORBES
JUN. 11, 2020
Under Armour Unveils Sportsmask, A Performance Facemask For Athletes



CNN
OCT. 13, 2020
Can antimicrobial fashion protect you from the coronavirus?




FASTCOMPANY
MAY 26, 2020
With this antiviral fabric coating, your clothing could protect you from COVID-19



CTV NEWS | TORONTO
AUG. 12, 2020
Article | Canadian biotech company says its anti-viral clothing kills 99.9 per cent of coronavirus



CTV NEWS | OTTAWA
AUG. 12, 2020
Broadcast Video | Canadian biotech company says its anti-viral clothing kills 99.9 per cent of coronavirus



BUSINESS INSIDER
JUN. 12, 2020
Under Armour's Sportsmask sold out in less than an hour, as people scramble to find masks



EVERYDAY HEALTH
JUL. 20, 2020
Can Antiviral Clothing Protect You From COVID-19?



ENGINEERING.COM
AUG. 20, 2020
Antiviral Clothing Aims to Shield Against COVID-19



NEWS STRAITS TIMES
JUL. 22, 2020
The Under Armour SportsMask is here



LS:N GLOBAL
MAR. 23, 2020
Antiviral Fabric for the Inter-COVID Era



ZOZO FASHION TECH | ENGLISH
AUG. 19, 2020
Functional fibre market attracting attention due to its antiviral effect: Canadian textile coating "PROTX2 AV"



ASI CENTRAL
MAY 26, 2020
Study: Antiviral Fabric Treatment Kills COVID-19



THE LIST
MAY 28, 2020
The next big fashion trend could be antiviral clothing

THANK YOU!

LEARN MORE AT WWW.IFABRICCORP.COM



525 Denison Street, Markham Ontario L3R1B8
905.752.0566 | www.ifabriccorp.com | info@ifabriccorp.com

HYLTON KARON

Group President & CEO
HyltonK@iFabricCorp.com
905.752.0566 x201
905.752.0567

HILTON PRICE

Chief Financial Officer
Hilton.Price@rogers.com
647.465.6161
905.752.0567

GIANCARLO BEEVIS

President & CEO | IFTNA
GC@iftna.com
905.752.0566 x202
905.752.0567

INVESTOR RELATIONS

STEVE HOSEIN

shosein@renmarkfinancial.com



iFabric Corp has been developing applications for antibacterial and antiviral soft surface applications. We will be the world's first company with a 'kill' claim, opening the global medical and apparel markets to our class leading technologies.

TSX: IFA | OTC-QX: IFABF

Contact Info:

E: info@ifabriccorp.com

T: 905.752.0566

W: www.ifabriccorp.com

February 1, 2022